Home / Health / Fat Cell Self-Destruction: New Injection Targets Visceral Fat
Fat Cell Self-Destruction: New Injection Targets Visceral Fat
12 Oct
Summary
- CBL-514 injection triggers fat cells to self-destruct via apoptosis.
- Phase 2 trials showed visceral fat decreased with CBL-514, not placebo.
- This new method targets deep visceral fat, unlike liposuction.
Early human trials for an experimental injection named CBL-514 are yielding encouraging results for reducing visceral fat. This deep abdominal fat poses significant health risks, including impacting metabolism and increasing insulin resistance. Two phase 2 trials investigated CBL-514's efficacy in diminishing these dangerous fat deposits.
Participants receiving injections of CBL-514 into their lower abdomen demonstrated a notable decrease in visceral fat compared to a placebo group, as confirmed by MRI scans. The drug works by selectively initiating apoptosis, a process of programmed cell self-destruction, specifically within fat cells.
Four weeks post-treatment, the CBL-514 group experienced an average fat volume reduction of 12.01%, while the placebo group saw a slight increase. Beyond potential cosmetic benefits like a flatter stomach, the injection's ability to improve weight, blood pressure, and cholesterol levels highlights its significant health implications. This contrasts with liposuction, which cannot remove visceral fat or mitigate its associated health risks.
